Swiss Biotech Vitroscope Raises $7 Million to Scale Perfusion Platform for Drug Discovery
Swiss biotech Vitroscope secured $7 million (a $5 million seed round co‑led by Cerberus Ventures and YZR Capital and $2 million of non‑dilutive funding from the Research Council of Norway) to bring its automated perfusion platform for living human tissue to more labs and develop a higher‑throughput version. The funding brings the company’s total capital raised to $8.8 million.